Axsome Therapeutics Business Summary

Axsome Therapeutics, Inc. (AXSM) is a commercial-stage biopharmaceutical company that generates revenue primarily through the direct sale of proprietary therapies targeting central nervous system (CNS) disorders. The company operates as a single business segment, leveraging its MoSEIC™ and Metabolic Barrier technology platforms to develop and commercialize a portfolio that includes Auvelity (major depressive disorder), Sunosi (excessive daytime sleepiness), and the recently launched Symbravo (acute migraine). As of February 2026, Axsome is transitioning into a multi-asset powerhouse with a late-stage pipeline featuring AXS-05 for Alzheimer’s disease agitation and AXS-12 for narcolepsy, both nearing pivotal regulatory milestones. Its primary competitors include Jazz Pharmaceuticals, AbbVie, and the partnership of Otsuka and Lundbeck; Axsome distinguishes itself in this crowded market by offering "rapid-acting" labels and non-antipsychotic safety profiles that challenge the efficacy and side-effect benchmarks of traditional SSRIs and atypical antipsychotics. The company was founded in 2012 by Dr. Herriot Tabuteau, who continues to serve as Chairman and CEO, bringing a pedigree that includes an MD from Yale and a background in healthcare investment at Goldman Sachs and HealthCor. The executive leadership team is further bolstered by CFO Nick Pizzie, formerly of Pfizer and Pierre Fabre, and COO Mark Jacobson, who previously led corporate development at Stemline Therapeutics. Axsome’s strategic direction is guided by a high-profile Board of Directors featuring industry veterans such as Dr. Roger Jeffs (former Co-CEO of United Therapeutics) and Dr. Susan Mahony (former President of Lilly Oncology). The company maintains a strong institutional investor base, with approximately 71% of shares held by major entities including State Street and Franklin Resources, reflecting significant market confidence in its commercial execution and R&D trajectory.